A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Placebo for ALXN2220Wainzua 45 mg solution for injection in pre-filled penRecombinant human anti-ATTR immunoglobulin G1 (IgG1) monoclonal antibody (mAb)
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
Change from baseline in CPET peak VO2
Endpoint detail
Change from baseline in ECV (subgroup)., Change from baseline in NT-proBNP., Change from baseline in KCCQ-CSS.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.